Form 8-K · Current report
Masco 8-K, filed Jul 29, 2026
- Filed
- CIK
- 0000062996
- Accession no.
- 0000062996-26-000026
Summary
Masco Corporation reported second quarter 2026 results with net sales down 3 percent to $1,992 million, adjusted earnings per share up 26 percent to $1.64, and $454 million returned to shareholders through dividends and buybacks. CEO Jon Nudi said the company raised its 2026 adjusted earnings per share guidance to $4.40–$4.60 from $4.10–$4.30, citing an anticipated full-year net benefit of about $85 million from IEEPA tariff refunds, after recognizing roughly $95 million of such refunds in the quarter.
Key points
- Second quarter net sales fell 3 percent to $1,992 million, with Plumbing Products down 3 percent and Decorative Architectural Products down 4 percent.
- Reported operating profit rose 14 percent to $470 million and operating margin rose to 23.6 percent; adjusted operating margin was 24.2 percent.
- Reported earnings per share were $1.60 and adjusted earnings per share were $1.64, up from $1.30 a year earlier.
- Liquidity at the end of the quarter was $1,548 million, including revolver availability.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. Attached and incorporated herein by reference as Exhibit 99 is a copy of the press release dated July 29, 2026 reporting Masco Corporation’s financial results for the second quarter 2026 and certain other information and supplemental information prepared for use in connection with the financial results for the second quarter 2026. On July 29, 2026, Masco Corporation will hold an investor conference call and webcast to discuss financial results for the second quarter 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.